This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quintiles Wins Society For Clinical Research Sites’ 2013 Eagle Award

Quintiles today announced that the company has been awarded the Society for Clinical Research Sites’ (SCRS) 2013 Clinical Research Organization (CRO) Eagle Award. The award recognizes outstanding leadership, professionalism, integrity, passion and dedication and is voted on by the sites themselves.

“Quintiles recognizes the vital and important role our dedicated and highly skilled investigators and their site teams play in conducting clinical research aimed at developing new and better medicines,” said Lindy Jones, senior vice president, Integrated Site Services, Quintiles. “We are thrilled to receive the Eagle Award which recognizes that we understand and are dedicated to working closely with all of our investigative sites. We are especially pleased because we were chosen by the sites themselves.”

“We are delighted to present the Eagle Award to Quintiles,” said SCRS President Christine Pierre. The award reflects the opinions of more than 1,000 investigative sites across the globe. Quintiles’ integrity in consistently demonstrating their keen interest in partnering with sites landed them with this prestigious recognition.”

In selecting this year’s nominees, investigative sites registering for the Site Solutions Summit were asked to nominate the sponsor and CRO they believe best demonstrate partnership commitment. Criteria for selection included availability of qualified staff to support the sites, willingness to collaborate, protocol design and execution, financial consideration, and partnering with sites for future work. Finalists were those sponsors and CROs that ranked in the 75th percentile or greater of nominations received. Once the finalists were identified, voting was open to all sites globally.

Of the participating sites, 60% were from North America, 23% from Europe, 7% from South America, 3% from Asia-Pacific, 3% from Sub Saharan Africa, and 4% from “other.” Those who participated in the survey were mostly investigators (35%), site directors (31%), and study coordinators (21%).

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

About SCRS

SCRS is a trade organization representing global clinical research sites representing sites in 22 countries. SCRS’ mission is to unify and amplify the voice of the global clinical research site community. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will benefit from membership. Visit www.myscrs.org.

Click here to subscribe to Mobile Alerts for Quintiles.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs